Swiss late-stage biotech Pharvaris saw its shares rise 17% to $28.24 today, as it announced RAPIDe-3 pivotal data confirming ...
Privately-held Imvax, a biotech developing personalized, whole tumor-derived immunotherapies, has announced top line results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback